Fig. 5
NCGHD annotations of driver genes. a Example of the type of annotation provided in NCGHD for cancer and healthy drivers (in this case PTEN). Annotation boxes can be expanded for further details, with the possibility of intersecting data interactively (for example, in the case of protein-protein or miRNA-gene interactions) and downloading data for local use. b Proportion of Reactome levels 2–8 enriched pathways mapping to the respective level 1 in each driver group. Enrichment was measured comparing the proportion of drivers in each pathway to that of the rest of human genes with a one-sided Fisher’s exact test. FDR was calculated using Benjamini-Hochberg. The numbers of drivers and enriched Reactome pathways are reported for each group. Proportion of canonical and candidate cancer divers and rest of genes that are (c) targets of FDA-approved antineoplastic drugs or biomarkers of response or resistance to oncological drugs in (d) cancer cell lines and (e) clinical studies. The corresponding numbers for each group are also shown